Blackrock Neurotech
Focus: Blackrock Neurotech is a specialized biotechnology company focused on brain-computer interface (BCI) technology, headquartered in Salt Lake City and founded in 2008. The company operates in the neurology space with a single active clinical program targeting severe motor impairment.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Open Jobs
6
Should You Work at Blackrock Neurotech?
AI assessmentBlackrock Neurotech is a high-risk, high-reward opportunity for scientists and engineers willing to bet on BCI adoption and accept pre-commercial company uncertainty in exchange for technical leadership in an emerging field.
Why Work Here
- Pioneering BCI technology platform with direct patient impact—the INTENT Neural Interface System targets tetraplegia, a condition with no existing pharmaceutical solutions.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
INTENT Neural Interface System
Tetraplegia/TetraparesisOpen Jobs (6)
Help build intelligence for Blackrock Neurotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.